Literature DB >> 20697258

Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.

Michael S Bronze1, James B Dale.   

Abstract

Infections caused by virulent Gram-positive bacteria, such as Staphylococcus aureus, group B streptococci and group A streptococci, remain significant causes of morbidity and mortality despite progress in antimicrobial therapy. Despite significant advances in the understanding of the pathogenesis of infection caused by these organisms, there are only limited strategies to prevent infection. In this article, we review efforts to develop safe and effective vaccines that would prevent infections caused by these 3 pathogens.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697258      PMCID: PMC2935929          DOI: 10.1097/MAJ.0b013e3181e939ab

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  128 in total

1.  Binding of human plasma proteins to Streptococcus pyogenes M protein determines the location of opsonic and non-opsonic epitopes.

Authors:  Charlotta Sandin; Fredric Carlsson; Gunnar Lindahl
Journal:  Mol Microbiol       Date:  2006-01       Impact factor: 3.501

2.  DNA-protein immunization against the GapB and GapC proteins of a mastitis isolate of Staphylococcus aureus.

Authors:  Oudessa Kerro-Dego; Tracy Prysliak; Andrew A Potter; Jose Perez-Casal
Journal:  Vet Immunol Immunopathol       Date:  2006-06-13       Impact factor: 2.046

Review 3.  Prevention of Staphylococcus aureus infections: advances in vaccine development.

Authors:  Henry R Shinefield; Steven Black
Journal:  Expert Rev Vaccines       Date:  2005-10       Impact factor: 5.217

4.  Immunization with glutathione S-transferase and mutant toxic shock syndrome toxin 1 fusion protein protects against Staphylococcus aureus infection.

Authors:  Jing-Chun Cui; Dong-Liang Hu; Yan-Chun Lin; Ai-Dong Qian; Akio Nakane
Journal:  FEMS Immunol Med Microbiol       Date:  2005-02-10

5.  Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines.

Authors:  John B Robbins; Rachel Schneerson; Gary Horwith; Robert Naso; Ali Fattom
Journal:  Am Heart J       Date:  2004-04       Impact factor: 4.749

Review 6.  Staphylococcal vaccines and immunotherapies.

Authors:  Adam C Schaffer; Jean C Lee
Journal:  Infect Dis Clin North Am       Date:  2009-03       Impact factor: 5.982

7.  Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design.

Authors:  Jasdeep S Nanra; Yekaterina Timofeyeva; Sandra M Buitrago; Bret R Sellman; Deborah A Dilts; Pamela Fink; Lorna Nunez; Michael Hagen; Yury V Matsuka; Terri Mininni; Duzhang Zhu; Viliam Pavliak; Bruce A Green; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Vaccine       Date:  2009-02-05       Impact factor: 3.641

8.  BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus.

Authors:  Isabella Santi; Domenico Maione; Cesira L Galeotti; Guido Grandi; John L Telford; Marco Soriani
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

Review 9.  Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials.

Authors:  Ali I Fattom; Gary Horwith; Steve Fuller; Myra Propst; Robert Naso
Journal:  Vaccine       Date:  2004-02-17       Impact factor: 3.641

10.  Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A.

Authors:  A Fattom; R Schneerson; D C Watson; W W Karakawa; D Fitzgerald; I Pastan; X Li; J Shiloach; D A Bryla; J B Robbins
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.609

View more
  2 in total

1.  Structural vaccinology to thwart antigenic variation in microbial pathogens.

Authors:  Olaf Schneewind; Dominique Missiakas
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

2.  StreptInCor: a candidate vaccine epitope against S. pyogenes infections induces protection in outbred mice.

Authors:  Edilberto Postol; Raquel Alencar; Fabio T Higa; Samar Freschi de Barros; Lea M F Demarchi; Jorge Kalil; Luiza Guilherme
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.